AbbVie is navigating significant shareholder activism as it urges opposition to two governance proposals ahead of its May 2025 meeting, fostering investor attention. Despite reporting a Q4 net ...

AbbVie Inc. (NYSE:ABBV) entered the obesity race last week when it in-licensed GUB014295 (also called GUBamy) from Denmark-based Gubra. The candidate is a long-acting amylin analog for the ...

AbbVie’s immunology blockbusters Rinvoq and Skyrizi took the first and second slots, respectively, for the month, resuming the custom they upheld throughout most of 2024. Those gains over ...

AbbVie’s former CEO Richard Gonzalez—who collected a $25.7 million payout for his final full year on the job in 2023—often ranked among the industry’s highest-paid CEOs during his tenure ...

US drugmaker AbbVie has agreed to buy struggling Allergan in a $63 billion deal that continues a slew of multibillion dollar takeovers in the biopharma sector this year. AbbVie is stumping up more ...

AbbVie has broken ground on a new $223 million expansion of its biologics manufacturing facility in Singapore, creating around 100 new jobs. The new investment will grow its workforce at the site ...

After hours: March 14 at 7:58:28 PM EDT ...

Pre-Market: 6:39:20 a.m. EDT Loading Chart for ABBV ...

After hours: 7:52:08 pm GMT-5 Loading Chart for ABBV ...